News stories about Chemed (NYSE:CHE) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chemed earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.4295275051849 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Chemed (CHE) Upgraded by ValuEngine to “Buy” (americanbankingnews.com)
- Chemed (CHE) Rating Increased to A- at TheStreet (americanbankingnews.com)
- Royal Bank of Canada Boosts Chemed (CHE) Price Target to $232.00 (americanbankingnews.com)
- Chemed Co. (CHE) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- LHC Group (LHCG) & Chemed (CHE) Critical Review (americanbankingnews.com)
Shares of NYSE:CHE traded up $3.20 on Thursday, hitting $281.39. 82,289 shares of the company were exchanged, compared to its average volume of 111,231. The company has a market cap of $4,422.04, a price-to-earnings ratio of 51.90, a PEG ratio of 2.55 and a beta of 1.06. Chemed has a one year low of $178.44 and a one year high of $285.79. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.88 and a current ratio of 0.91.
The firm also recently announced a quarterly dividend, which was paid on Monday, March 19th. Investors of record on Monday, February 26th were paid a $0.28 dividend. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a yield of 0.40%. Chemed’s payout ratio is currently 20.90%.
Chemed announced that its board has authorized a share buyback plan on Tuesday, March 6th that allows the company to repurchase $150.00 million in outstanding shares. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
CHE has been the topic of several research reports. Royal Bank of Canada restated a “hold” rating and set a $258.00 price objective on shares of Chemed in a report on Friday, February 16th. Oppenheimer boosted their price objective on shares of Chemed from $270.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, February 16th. Finally, ValuEngine upgraded shares of Chemed from a “hold” rating to a “buy” rating in a report on Monday. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $261.33.
In other Chemed news, VP Naomi C. Dallob sold 1,050 shares of the business’s stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $257.00, for a total value of $269,850.00. Following the transaction, the vice president now directly owns 6,649 shares in the company, valued at $1,708,793. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Kevin J. Mcnamara sold 6,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $258.00, for a total transaction of $1,548,000.00. Following the completion of the transaction, the insider now owns 140,049 shares in the company, valued at $36,132,642. The disclosure for this sale can be found here. Insiders own 4.90% of the company’s stock.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.